A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

Inclusion Criteria: * 18\~65 years old (including lower limit), no gender limit； * You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study； * You must have active plaque psoriasis covering at least 10% body surface area； You must have Psoriasis Area and Severity Index (PASI) score of at least 12；You must have Static Physician's Global Assessment (sPGA) score of at least 3； * The patient can communicate well with the investigator and follow the research and follow-up procedures； * Understand and voluntarily sign the informed consent form. Exclusion Criteria: * You must not have prior treatment with an oral Janus kinase (JAK) inhibitor； * You must not have received a phototherapy within 4 weeks prior to entry into the study； * You must not have a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)； * You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse